Sickle Cell Disease Clinical Trials in Houston, Texas

10 studies are recruiting for sickle cell disease in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Texas Children's Hospital_Houston, Houston, Texas

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   UT Health University of Texas, Houston, Texas

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Texas Childrens Cancer and Hematology Center, Houston, Texas

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

4. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants …

   Stage

   Phase 1

   Ages

   12 to 55

   Site

   UT Health Science Center, Houston, Texas

   Locations

   10 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06546670 on ClinicalTrials.gov

5. A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

   The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

   Stage

   Phase 2

   Ages

   12 and older

   Site

   McGovern Medical School at UTHealth, Houston, Texas

   Locations

   80 in total

   Run by

   Pfizer

   See if you can join NCT05431088 on ClinicalTrials.gov

6. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Gulf States Hemophilia and Thrombophilia Center, Houston, Texas

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

7. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study detai…

   Stage

   Phase 3

   Ages

   10 to 65

   Site

   Baylor College of Medicine- Site Number : 8400055, Houston, Texas

   Locations

   53 in total

   Run by

   Sanofi

   See if you can join NCT06975865 on ClinicalTrials.gov

8. Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

   The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Site # 8400004, Houston, Texas

   Locations

   7 in total

   Run by

   Sanofi

   See if you can join NCT07247188 on ClinicalTrials.gov

9. Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

   The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most r…

   Stage

   Phase 2

   Ages

   15 to 40

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   6 in total

   Run by

   University of California, San Francisco

   See if you can join NCT06260891 on ClinicalTrials.gov

10. Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

    The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Texas at Houston, Houston, Texas

    Locations

    9 in total

    Run by

    RTI International

    See if you can join NCT06385886 on ClinicalTrials.gov